You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
BGI will establish six so-called Huo-Yan COVID-19 testing labs in Saudi Arabia, based on the emergency lab the firm set up in Wuhan, China in February.
The RT-PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in a range of upper and lower respiratory specimens including nasal swabs and sputum.
All three tests use upper respiratory specimens such as nasal swabs, but the AIT and MicroGenDx tests can also use sputum samples.
Novacyt has initially committed to supply 288,000 tests per week to the DHSC, and it has an option to expand the agreement.
The firm's Continuum system is fully automated and performs the entire digital PCR workflow in a single instrument.
Vela anticipates CE-IVD marking for an automated version of its test, and JN Medsys has received authorization for its test in Singapore and the Philippines.
The test is designed for the detection of nucleic acid from SARS-CoV-2 in nasopharyngeal, oropharyngeal, nasal, and mid-turbinate nasal swab specimens as well as sputum.
Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.
The partners received Emergency Use Authorization last week for a test that uses oral fluids, and the lab has capacity to test up to 10,000 samples per day.
The PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in various respiratory specimens including oropharyngeal and nasopharyngeal swabs.
The firm is looking into options for partnerships to bring a COVID-19 serology test to market, which could leverage its large installed base of instruments.
The two UK companies are validating GeneFirst's assay for use with Rapid Dx's Rapid Minilab RT-PCR Desktop Point of Care Platform.
MBS has developed a compact endpoint PCR system which can test more than 22,000 patient samples per day by performing eight-minute thermal cycling.
Combining Ubiquitome's handheld PCR device and Oxford Nanopore's sequencer may enable a single person to screen 500 samples and obtain 24 whole genome sequences per day.
The Novodiag COVID-19 real-time PCR assay enables on-demand and fully automated detection of early COVID-19 infections in about one hour, the firm said.
The firm said as part of a development study it is using a gut microbiome analysis tool developed in collaboration with Thermo Fisher Scientific.
The PCR-based assay is designed to detect RNA from the virus' nucleocapsid and ORF1ab genes in upper and lower respiratory specimens.
Emergency testing related to the SARS-CoV-2 pandemic strongly increased, but routine testing declined due to fewer regular health checks.
The test was already authorized for use in Canada and South Korea. Seegene has sold more than 10 million of the assay in more than 60 countries.
The test is designed to detect SARS-CoV-2 E and RDRP genes in nasal, nasopharyngeal, and oropharyngeal swabs, as well as bronchoalveolar lavage specimens.
Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.
Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.
Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.
In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.